Clinical Trials Browser

Phase 1 × nintedanib × Other hematologic neoplasm × Clear all

NCT03513484 2025-10-21

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute